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Chronic nonbacterial osteomyelitis (CNO) with its most severe form chronic recurrent multifocal osteomyelitis (CRMO) is a
non-bacterial osteitis of yet unknown origin. Secondary to the absence of both high-titer autoantibodies and autoreactive T
lymphocytes, and the association with other autoimmune diseases, it was recently reclassiﬁed as an autoinﬂammatory disorder
of the musculoskeletal system. Since its etiology is largely unknown, the diagnosis is based on clinical criteria, and treatment is
empiric and not always successful. In this paper, we summarize recent advances in the understanding of possible etiopathogenetic
mechanisms in CNO.
1.Introduction
Chronic nonbacterial osteomyelitis (CNO) (OMIM number
259680) is an autoinﬂammatory, noninfectious disorder that
aﬀectstheskeletalsystemandhasﬁrstbeendescribedin1972
[1]. An association with further autoimmune and autoin-
ﬂammatory disorders such as pustolusis palmoplantaris [2],
chronic inﬂammatory bowel disease (IBD), psoriasis, c-
ANCApositivevasculitis,Takayasu’sarteriitis,anddeﬁciency
of IL-1 receptor antagonist (DIRA) has been discussed [3–5].
CNO covers a wide clinical spectrum from non- or oligo-
symptomatic monofocal bony lesions to its most severe
form chronic recurring multifocal osteomyelitis (CRMO).
Generally, any skeletal site can be aﬀected. However, meta-
physes of long bones are predominantly involved [6]w i t ha
predilection for the lower extremities (distal femur, proximal
tibia, distal tibia, and distal ﬁbula [7]), followed by the
clavicle and spine. A symmetric involvement is common.
Systemic symptoms occur in a subset of patients and include
low-grade fevers and malaise. Even though Scully et al.
(2008) [7] reported a predominance in females (up to 85%),
larger studies did not conﬁrm this.
However, little is known about the pathophysiology of
CNO.MostresearcharticlesfocusonclinicalaspectsofCNO,
and only few reports discuss putative pathomechanisms
underlying this autoinﬂammatory disorder.
2.Classiﬁcation,ClinicalPicture,
Diagnosis,and Treatment
Autoinﬂammatory diseases are rare disorders, characterized
by recurrent episodes of fever and inﬂammation, and mostly
aﬀect joints, serosal surfaces, eyes and skin in the absence
of high-titer autoantibodies, autoreactive T lymphocytes
[11], and underlying infection [7]. In 2006, McGonagle
and McDermott [12] suggested a clinical continuum with
autoimmune disorders on the one, and autoinﬂammatory
diseases on the other end of the spectrum. Disorders located
towards the middle of the continuum exhibit features of
both autoinﬂammatory as well as autoimmune diseases.
According to this deﬁnition, CNO has been classiﬁed as
an autoinﬂammatory disorder. In CNO the diagnosis relies
on clinical symptoms, systemic inﬂammation, and elevated2 International Journal of Rheumatology
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Figure 1: (a) left panel: computerized tomography (CT) of the spine, showing an osteolytic lesions (white arrow) in chronic recurrent
multifocal osteomyelitis in a thoracic vertebra. Right panel: radiograph of the spine, showing ﬂattening of the third lumbar vertebra (white
arrows) in chronic recurrent multifocal osteomyelitis. (b) magnetic resonance imaging (MRI) in a patient with chronic recurrent multifocal
osteomyelitis; left panel: whole-body MRI, showing multiple foci of osteomyelitis, some of which are distributed symmetrically; right panel:
magniﬁed image (from the left panel) of the knees, showing inﬂammatory epiphyseal lesions in both tibiae.
acute phase proteins during attacks. In very few cases, under-
lyingmutationsintherelevantgenescanbedetected(Majeed
syndrome, see below). CNO needs to be diﬀerentiated from
infectious osteomyelitis, including mycobacterial infections,
and malignant neoplasms.
Laboratory and histopathological ﬁndings are nonspe-
ciﬁc, with mildly elevated acute phase markers, and plas-
macellular, granulocytic, and monocytic inﬁltrations respec-
tively [13]. However in a substantial number of patients,
systemic inﬂammatory signs (such as low-grade fever and
malaise and elevated acute phase proteins) cannot be found,
even during attacks. In these cases, the diagnosis of CNO can
be made, combining clinical ﬁndings (localized bone pain,
swelling, and warmth in the aﬀe c t e da r e a s )a n dl a b o r a t o r y
tests (including testing for mycobacteria) with radiographic
techniques.Thepresenceofosteolyticlesionswithsurround-
ing sclerosis in X-ray imaging, supplemented by computer-
ized tomography (CT) and/or magnetic resonance imaging
(MRI), is usually helpful (Figure 1). Silent asymptomatic
lesions frequently appear on nuclear scans.
Even though CNO has been treated with azithromycin
[14] in the past, it does generally not respond to antibi-
otics. Treatment involves anti-inﬂammatory agents, includ-
ing NSAIDs [13, 15, 16] and corticosteroids. In treatment
restistant cases, bisphosphonates [17] and biologicals, usu-
allyinﬂiximaboretanercept(blockingtumornecrosisfactor-
α)[ 18] have been applied successfully, suggesting an involve-
ment of TNF-α in the pathophysiology of CNO.
Individual clinical courses of CNO are generally unpre-
dictable. Most cases are self-limiting and eventually resolve
withoutmajorsequelae.However,asubsetofpatientsexhibit
severe and prolonged disease courses and are at risk of
developingbonedeformitiesthatcanbecausedbypremature
closure of the epiphyses, and kyphoscoliosis as a result of
vertebral involvement [4, 6, 19]. Disease onset at a young
age and high numbers [20] of inﬂammatory bone lesions at
disease onset seem to be predictive of poor outcomes [4, 19].
3.PutativePathomechanisms
Imbalances in cytokine expression can cause a disruption
of immune homeostasis, resulting in increased or reduced
inﬂammatory responses that in turn may cause susceptibility
to infections or autoimmune disorders. Cytokine dysregula-
tion can be caused on various levels, including (1) impaired
transcription that can be caused by genomic variation and
(2) epigenetic modiﬁcations. Genomic variations, includ-
ing single-nucleotide polymorphisms (SNPs), can inﬂuence
gene expression by variable transcription factor binding or
variation in genome organization [21]. Epigenetic modiﬁ-
cations alter chromatin accessibility for transcription factors
and/or RNA polymerases [21, 22]. Posttranslational histone
modiﬁcations inﬂuence the transcriptional activity of genes
and serve as markers of epigenetic changes. Histone hyper-
methylation as repressing histone modiﬁcation mediates
dense packing of nucleosomes in transcriptionally silent, so-
called “heterochromatic” regions. Activating histone modi-
ﬁcations, such as histone acetylation and phosphorylation,
mediate “open” or “euchromatic” chromatine conformation
that is accessible for transcriptional regulatory factors and
RNA polymerases [8].
3.1. Genetic Susceptibility Studies. Genetic studies suggested
a predisposing locus for CNO on chromosome 18q21.3-
18q22 [23]. However, convincing evidence for the involve-
ment of this locus in the pathophysiology of CNO is still
lacking. Several observations suggest the contribution of
genetic factors to the etiology of CNO.
Fergusonetal.[24,25]describedhomozygousmutations
in the LPIN2 gene, causing a syndromic autosomal recessiveInternational Journal of Rheumatology 3
form of CNO known as Majeed syndrome. The Majeed syn-
drome’s classical triad includes early-onset CRMO, congeni-
tal dyserythropoietic anemia and a neutrophilic dermatosis.
It is an extremely rare disease and has only been identiﬁed
in three unrelated Arabic families [14, 26]. Bone lesions in
Majeed syndrome occur within the ﬁrst two years of life,
and the course is more aggressive then in CNO, with more
relapses. LPIN2 was mapped to chromosome 18p and found
to be expressed in almost all tissues [25]. Little is known
about the function of LPIN2. It shares a lipin domain with
the human ortholog of murine lpin1, which plays a role in
fat metabolism. Because of the dyserythropoesis in Majeed
syndrome, it has been proposed that LPIN2 could also play
a role in mitosis, and that an impaired function may lead
to abnormal mitosis in rapidly dividing cells, including the
red blood cell lineage in the bone marrow [25]. It has
further been hypothesised that mutations in LPIN2 may
play an etiologic role in psoriasis, since it localizes to a
genomic region identiﬁed as a psoriasis susceptibility locus.
Furthermore, all carriers of disease causing homozygous
LPIN2 mutations exhibit inﬂammatory dermatoses [25].
Mutations in the pstpip2 gene have been described in the
murine form of CNO [27]. To date, there are two murine
CNO models, both carrying mutations in the pstpip2 gene:
(1)cmomice[26–29]and(2)Lupomice[30].Cmo(chronic
multifocal osteomyelitis) mice have been reported to develop
a phenotype that is similar to severe cases of human
CNO with multiple sites of inﬂammation. However, most
CNO patients present with less severe mono- or oligo-focal
disease which does not completely resemble the disease in
cmo mice that develop multifocal (systemic) inﬂammatory
symptoms. The disease is inherited in an autosomal recessive
manner, and the cmo locus has been mapped to the murine
chromosome 18 [27]. Within the reﬁned region was the
gene pstpip2, which shares signiﬁcant sequence homol-
ogy to human PSTPIP1. Expression patterns of murine
Pstpip2, also called MAYP (macrophage actin-associated
tyrosine-phosphorylated protein), are discussed controver-
sially. While Pstpip2 mRNA is ubiquitously expressed [31],
Western blot analysis revealed narrow protein expression
patterns, with the highest Pstpip2 expression in myeloid cells
[32]. Pstpip2 plays a role in cytoskeletal reorganization, and
localizes to the cytosol as an F-actin associated phospho-
protein that interacts with PEST-type protein tyrosine phos-
phatases (PTP PEST) [31, 32]. The association with PEST
family PTPs inhibits tyrosine phosphorylation of wildtype
PSTPIP1 [33]. Mutations in the PSTPIP1 gene have been
documented to cause the autoinﬂammatory PAPA syndrome
(pyogenic arthritis, pyoderma gangrenosum, and acne). The
PSTPIP1 protein binds to pyrin, a regulator that inhibits the
NLRP3 inﬂammasome. Interestingly, Veillette et al. [33]a n d
Wise et al. [34] demonstrated that the PSTPIP1 mutations
found in the autoinﬂammatory PAPA syndrome are in the
putativecoil-coildomainofPSTPIP1,abolishingthecapacity
of PSTPIP1 to bind PEST family PTPs. This alteration
results in enhanced PSTPIP1 tyrosine phosphorylation and
is accompanied by augmented binding of PSTPIP1 to pyrin
via an SH3 domain [10], resulting in constitutive activation
of NLRP3, production of IL-1β, and inﬂammation [33]
(Figure 2). Some similarities in the phenotypes of cmo mice
and (human) PAPA patients may suggest an involvement
of the same or similar immunologic pathways. However,
the absence of the SH3 domain in Pstpip2 suggests that
it does not bind pyrin directly [27]. However, “classical”
CNO patients do not develop the characteristic pustulotic or
pyogenic dermatitis that is seen in PAPA patients.
Even though cmo mice serve as an interesting model for
bone inﬂammation, none of the reported CNO patients [35]
carry mutation in the PSTPIP1 and PSTPIP2 genes, except
for several known polymorphisms.
The recent report of a condition, presenting with neona-
tal onset sterile multifocal osteomyelitis, periostosis, and
pustulosis, that is caused by a deﬁciency of IL-1 receptor
antagonist (DIRA), is of special interest [5]. Because of
similarclinical,radiologicalandhistologicalfeaturesofCNO
and DIRA, both disorders might share common or similar
autoinﬂammatory processes. However, in a recent study [36]
a heterozygous missense mutation c.281G>T (p.Cys94Phe)
could only be found in one patient with CNO. In the other
patients, only frequent polymorphisms were found.
Another hint towards the understanding of genetic
contributors to the pathophysiology of CNO may be the
clinical similarities of CNO patients and patients with hy-
pophosphatasia [37, 38]. Hypophosphatasia is a rare defect
of bone metabolism that is caused by a number of mu-
tations in the gene encoding for the tissue-nonspeciﬁc
alkaline phosphatase (TNSALP) on chromosome 1p36.1.
The mode of inheritance is mostly autosomal-recessive [37,
39,40].TNSALPmutationsresultinreducedenzymeactivity
and elevated concentrations of TNSALP substrates, includ-
ing inorganic pyrophosphate, pyridoxal-50-phosphate and
phosphoethanolamine [41–43]. It has been documented that
pyrophosphate crystals stimulate the NLRP3 inﬂammasome
resulting in Interleukin-1 production [44]. An inﬂammatory
processsecondarytothemetabolicdefectinhypophosphata-
sia involving the NLRP3 inﬂammasome may therefore be
involved in the pathogenesis of CNO.
Since associations between CNO and Crohn’s disease, a
multifactorial autoinﬂammatory disease, have been reported
[26], Morbach and colleagues [45] analyzed CNO patients
for NOD2/CARD15 mutations. However, CNO without
intestinal inﬂammation was not associated with common
CARD15 gene variants [45].
In addition, susceptibility regions have been identiﬁed
on chromosome 18 in two other diseases sharing similarities
with CNO: familial expansile osteolysis and familial Paget’s
disease of bone [26, 46, 47]. The phenotypes of both diseases
have been linked to mutations in the TNFRSF11A gene at
18q22.1, which encodes the receptor activator of nuclear
factor kappa B (RANK) [46, 47].
Recently, we reported an association of CNO with IL10
promoter polymorphisms [3, 8]. IL-10 is an immune-
regulatory cytokine that controls inﬂammation by limiting
inﬂammatory cytokine expression and antigen presentation.
Dysregulation in IL-10 expression, sometimes caused by
single-nucleotide polymorphisms (SNPs) in the IL10 pro-
moter have been associated to autoimmune and infectious
diseases, such as SLE [48], asthma, chronic viral diseases,4 International Journal of Rheumatology
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Figure 2: Possible pathophysiological mechanisms in autoinﬂammatory diseases with emphasis on CNO. Modiﬁed from [8, 9]. Endogenous
and exogenous danger signals (danger-associated molecular patterns: DAMPs and pathogen-associated molecular patterns: PAMPs) activate
the NLRP3 inﬂammasome that is involved in various autoinﬂammatory disorders. The exact pathways that result in NLRP3 activation
are yet unknown. However, reactive oxygen species (ROS) and lysosomal destabilization seem to be involved. The selected monogenic
autoinﬂammatory syndromes result in an activation of the caspase-1 complex. In PAPA, mutations in PSTPIP1 lead to prolonged binding
of PSTPIP1 to pyrin via an SH3 domain [10] and impairment of pyrin function, resulting in constitutive activation of NLRP3, production
of IL-1β, and inﬂammation. IL-1 receptor antagonist (IL-1RA) is a naturally occurring IL-1β antagonist, and mutations in the IL1RA gen
lead to DIRA. Based on the ﬁnding that Sp1 binding to the IL10 promoter is reduced, and H3S10 phosphorylation is impaired in the same
region in monocytes from CNO patients, we concluded that processes upstream of Sp1 activation and H3S10 phosphorylation may be
involved. A reduced activity of MAP kinases upstream of Sp1 signalling may be responsible, resulting in reduced Sp1 activation and reduced
H3S10 phosphorylation of the IL10 proximal promoter. ASC: apoptosis-associated speck-like protein containing a caspase recruitment
domain; Casp1: enzymatically active caspase-1; IL-18: interleukin-18; IL-1β: interleukin-1β; NLRP3: NOD-like receptor family, pyrin
domain containing 3; pro-Casp1: procaspase-1; ROS: reactive oxygen species; CNO: chronic nonbacterial osteomyelitis; DIRA: deﬁciency
in IL-1 receptor antagonist; PAPA: pyogenic arthritis, pyoderma gangrenosum and acne; PSTPIP1: proline-serine-threonine phosphatase-
interacting protein 1.
rheumatoidarthritisaswellastransplantationcomplications
and cancer [49–51].
IL10 promoter polymorphisms as an example for
genomic variation, appear to play an important role in
the interindividual variation of IL-10 expression [8, 52].
TheIL10promoterpolymorphisms −1082G>A(rs1800869),
−819C>T (rs1800871), and −592C>A (rs1800872) are in
tight linkage disequilibrium and form three well-deﬁned
or “classical” haplotypes: ATA, ACC, and GCC [3]. ATA is
associated with low, ACC with intermediate, and GCC with
high levels of IL-10 expression [48, 53, 54]. However, for
the interindividual variability of IL-10 expression, additional
host factors seem to play an important role [52].
As aforementioned, an association of IL10 promoter
polymorphisms with CNO has been described [8], demon-
strating an increased frequency of high IL-10 expressing
−1082G/G alleles, and resulting GCC haplotypes. Inter-
estingly, monocytes from CNO patients failed to produce
IL-10 in response to stimulation with LPS. This could be
explained by (1) IL10 promoter polymorphisms as part of
larger haplotypes, extending several hundred kilobases over
the entire cytokine cluster, develop cumulative eﬀects in a
genomic setting [8]. This hypothesis is supported by a recent
study [55] that failed to ﬁnd a link between IL10 promoter
SNPs and inﬂammatory bowel disease (IBD), but showed
an association between a SNP 3  to the IL10 gene andInternational Journal of Rheumatology 5
ulcerative colitis. (2) since it is known that IL-10 mediates
the proliferation of various lymphocytic tissues, including B
cells, and enhances antibody production [56]. Lymphocytes,
butalsoplasmacellscanbepredominantlyfoundinbiopsies,
taken from CNO lesions. Having the anti-inﬂammatory
aspectsofIL-10expressioninmind,anassociationwithGCC
haplotypes could partly explain the lymphocyte expansion
in aﬀected tissues [6]. (3) additional, namely, epigenetic
mechanisms, could be involved in the dysregulation of
cytokine expression in CNO (see below).
3.2. Epigenetic Mechanisms. The expression of pro- and anti-
inﬂammatory cytokines, including IL-10, is considered to
be under epigenetic control. Zhang et al. [57]r e p o r t e d
histone-phosphorylation within the IL10 proximal promoter
tobeassociatedwithtranscription. Histonephosphorylation
is particularly increased in regulatory regions that bind
the transcription factor speciﬁcity protein 1 (Sp1) and 3
(Sp3) and mediate transcriptional activation in response to
stimulation with LPS [58–61]. We recently demonstrated
that monocytes from CNO patients fail to produce IL-10.
Since the proximal promoter region of IL10 displaysmultiple
GC rich sequences, which bind SP-family transcription
factors, the binding of the transcriptional regulatory factor
Sp1 (previously reported to play a role in the regulation
of IL-10 in monocytes and macrophages [55]) to the IL10
promoter has been investigated. A markedly reduced Sp1
recruitment to the IL10 636 Sp1 element has been detected
in monocytes from CNO patients in response to LPS
stimulation [8]. This was accompanied with reduced histone
H3 serine 10 phosphorylation (H3S10p), an activating
epigenetic mark. These ﬁndings indicate (1) reduced Sp1
recruitment and (2) attenuated H3S10 phosphorylation
around the IL10 636 element within the IL10 promoter
[8].
Given that (1) LPS stimulation induces MAP kinase
(MAPK) activation in monocytes and macrophages, includ-
ing the p38 [61], the ERKs 1 and 2, and the JNK MAPK
pathway [58], and (2) ERKs 1 and 2 are implicated in
H3S10 phosphorylation [62], these reports could indicate a
new pathophysiological mechanism in CNO with impaired
MAPK signaling, resulting in reduced H3S10 phosphor-
ylation, and Sp1 recruitment to the IL10 promoter and
subsequently attenuated gene expression and immune ho-
meostasis [8].
3.3. Other Possible Etiopathogenetic Mechanisms of CNO.
TNF-α and IL-1β are implicated in the pathophysiology
of various autoimmune and autoinﬂammatory disorders,
including CNO, where it has been documented to be
increasedininﬂammatorylesions[35].Furthermore,clinical
response to anti-TNFα or IL-1 receptor antagonist (IL-
1ra) anakinra treatment has been documented in CNO
( s u m m a r i z e di n[ 63]). However, it remains unclear whether
increased TNF-α and IL-1β expression is the pathophys-
iological cause of CNO or a downstream event in the
disease. The aforementioned reduced expression of IL-10
in monocytes from CNO patients may well contribute
to a cytokine imbalance towards proinﬂammatory signals,
including TNF-α.
4. Conclusions
Only few CNO cases have been associated with muta-
tions in single genes. However, they do not explain the
pathophysiology of CNO in the vast majority of cases.
Thus, neither the etiology nor the pathogenesis of CNO is
completely understood. Mutations in the TNFα and IL1RA
genes in humans and the Pstpip2 gene in mice appear to
be promising in the search for pathomechanisms in CNO.
The most recently described pathophysiological mechanism
in CNO might involve impaired MAPK signaling, reduced
H3S10 phosphorylation, and attenuated Sp1 recruitment
to the IL10 promoter that results in an impaired gene
expression.
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